Brought to you by
ECR 2019 / C-2625
Hybrid imaging in neuroendocrinal tumours, an overview
Congress: ECR 2019
Poster No.: C-2625
Type: Educational Exhibit
Keywords: Cancer, Diagnostic procedure, PET-CT, Molecular imaging
Authors: M. M. A. Rezk; Cairo/EG
DOI:10.26044/ecr2019/C-2625

References

Maxwell, J. E., & Howe, J. R. (2015). Imaging in neuroendocrine tumors: an update for the clinician. International journal of endocrine oncology2(2), 159-168.Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch. Surg. 2011;396(3):273–298. [PubMed]Yao JC, Hassan M, Phan A, et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008;26(18):3063–3072. [PubMed]Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531) Ann. Oncol. 2013;24(12):3040–3044. [PubMed]Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J. Cancer. 2012;3:292–302. [PMC free article][PubMed]Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. 2011;29(17):2416–2423. [PubMed]Bushnell DL, Baum RP. Standard imaging techniques for neuroendocrine tumors. Endocrinol. Metab. Clin. N. Am. 2011;40:153–162. [PubMed]

POSTER ACTIONS Add bookmark Contact presenter Send to a friend Download pdf
SHARE THIS POSTER
2 clicks for more privacy: On the first click the button will be activated and you can then share the poster with a second click.

This website uses cookies. Learn more